PT Pyridam Farma Tbk
Indonesia Stock ExchangeTotal Valuation
PT Pyridam Farma Tbk carries a market capitalization of 2.38T, placing it among publicly traded companies globally. Its enterprise value stands at 8.71T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.38T |
| Enterprise Value | 8.71T |
Share Statistics
PT Pyridam Farma Tbk currently has 11.24B shares outstanding.
| Shares Outstanding | 11.24B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.23, and the price-to-book ratio stands at 5.63.
| PE Ratio | N/A |
| PS Ratio | 1.23 |
| PB Ratio | 5.63 |
| P/TBV Ratio | -1.79 |
| P/FCF Ratio | 27.23 |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 3.07 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 24.46 |
Financial Position
PT Pyridam Farma Tbk maintains a current ratio of 0.86, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 539.74, indicating elevated leverage, while an interest coverage ratio of -0.53 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.86 |
| Quick Ratio | 0.03 |
| Debt / Equity | 539.74 |
| Debt / EBITDA | -29.49 |
| Interest Coverage | -0.53 |
Financial Efficiency
| Return on Equity (ROE) | -46.05 |
| Return on Assets (ROA) | -5.68 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.48 |
Taxes
| Income Tax | -153.81B |
| Effective Tax Rate | N/A |
Stock Price Statistics
PT Pyridam Farma Tbk's stock has declined approximately -7.01754% over the past 52 weeks. The 50-day moving average sits at 253.68, while the 200-day moving average is 408.30.
| Beta (5Y) | N/A |
| 52-Week Price Change | -7.01754% |
| 50-Day Moving Average | 253.68 |
| 200-Day Moving Average | 408.30 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, PT Pyridam Farma Tbk generated 2.84T in revenue and converted that into -369.95B in net income, yielding earnings per share of -32.92. EBITDA reached -171.63B, while operating income came in at -171.63B.
| Revenue | 2.84T |
| Gross Profit | 595.66B |
| Operating Income | -171.63B |
| Pretax Income | -523.76B |
| Net Income | -369.95B |
| EBITDA | -171.63B |
| EBIT | -171.63B |
| Earnings Per Share (EPS) | -32.92 |
Balance Sheet
PT Pyridam Farma Tbk holds 51.07B in cash and equivalents against 5.06T in total debt, resulting in a net debt position of 3.77T. Total book value stands at 618.32B, with working capital of -254.19B providing operational flexibility.
| Cash & Cash Equivalents | 51.07B |
| Total Debt | 5.06T |
| Net Debt | 3.77T |
| Equity (Book Value) | 618.32B |
| Book Value Per Share | 55.03 |
| Working Capital | -254.19B |
Cash Flow
After subtracting -127.91B in capital expenditures, free cash flow totaled -127.91B - equivalent to -11.38 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -127.91B |
| Free Cash Flow | -127.91B |
| FCF Per Share | -11.38 |
Margins
PT Pyridam Farma Tbk operates with a gross margin of 20.96, reflecting its pricing power and cost economics. The operating margin of -6.04 and net profit margin of -13.02 provide insight into operational efficiency.
| Gross Margin | 20.96 |
| Operating Margin | -6.04 |
| Pretax Margin | -18.43 |
| Profit Margin | -13.02 |
| EBITDA Margin | -6.04 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -10.42 |
| FCF Yield | 3.67 |
Stock Splits
PT Pyridam Farma Tbk's most recent stock split took place on April 22, 2024 with a 1000:4657 split ratio.
| Last Split Date | 4/22/2024 |
| Split Ratio | 1000:4657 |
Scores
PT Pyridam Farma Tbk posts an Altman Z-Score of 0.64, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.64 |